AQR Capital Management LLC Decreases Stock Position in Pulse Biosciences, Inc. (NASDAQ:PLSE)

AQR Capital Management LLC lowered its stake in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 13.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,195 shares of the company’s stock after selling 1,766 shares during the quarter. AQR Capital Management LLC’s holdings in Pulse Biosciences were worth $125,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of PLSE. Vanguard Group Inc. raised its position in shares of Pulse Biosciences by 28.8% during the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after buying an additional 189,227 shares in the last quarter. Griffin Asset Management Inc. raised its position in Pulse Biosciences by 15.7% in the 1st quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock worth $2,616,000 after purchasing an additional 40,700 shares during the period. Westside Investment Management Inc. raised its position in Pulse Biosciences by 97.8% in the 2nd quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock worth $712,000 after purchasing an additional 31,440 shares during the period. PNC Financial Services Group Inc. purchased a new stake in Pulse Biosciences in the 4th quarter worth about $242,000. Finally, Cetera Advisors LLC purchased a new stake in Pulse Biosciences in the 1st quarter worth about $109,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Price Performance

Shares of PLSE stock opened at $17.30 on Friday. The company has a market capitalization of $1.06 billion, a P/E ratio of -21.36 and a beta of 1.74. The company’s 50-day simple moving average is $17.87 and its two-hundred day simple moving average is $13.62. Pulse Biosciences, Inc. has a one year low of $3.78 and a one year high of $22.69.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research report on Friday, September 20th.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.